
BLOCKS
ROAD MAP
GOAL
Evidence on primaquine
• Pharmacology
» What's the active metabolite?
» Suitable drug partner?
• Safe and efficacious dose
• Safety by G6PD phenotype
Drug supply and regulation
Alternatives
Phase 1
Ex-vivo studies for efficacy and pharmacodynamics and pharmacokinetics
Phase 2
Dose escalation for safety and efficacy in high risk groups
Common endpoints
Phase 3
Community trials with surrogate marker endpoints
Phase 4
Determine safety in pregnancy through review of primaquine in pregnancy in countries using primaquine
Unsafe in G6PD—need to develop PoC test for phenotype
Identify stakeholders
Inclusion of stakeholders in road map
Development of gametocytocidal drugs, e.g., tafenoquine and methylene blue
Safe and efficacious dose for mass drug administration alone or in combination
Implemented
Product pipeline moving